Navigation Links
Lipitor News: Rottenstein Law Group LLP Comments on Boomers’ Favorite Drug
Date:6/20/2013

New York, NY (PRWEB) June 20, 2013

Drugs like Lipitor and its generic equivalents are poised to become Baby Boomers’ drug of choice, according to a June 19 MarketWatch report based on a Mayo Clinic study.* The Rottenstein Law Group LLP, which represents clients in Lipitor cases, acknowledges the report with some concern considering the allegations that Lipitor can cause women to develop type 2 diabetes.

The Mayo study found that among patients aged 50 to 64 two types of drugs are the most prescribed: cholesterol-reducing drugs, such as Lipitor, and antidepressants, according to the MarketWatch report. For those over the age of 65, drugs for treating cholesterol are the most widely used, indicating a growth in use as Boomers age.

“It is certainly a patient’s prerogative to use a drug prescribed to treat her high cholesterol,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “But it is important to note that there is currently ongoing litigation over the drug’s potential to increase the risk of developing type 2 diabetes in its users, especially women. Not only do we hear about this in the phone calls we receive from prospective and current clients, but it's also in several published research studies.”

Nationwide Lipitor lawsuits are currently under consideration for consolidation into a federal multidistrict litigation for pretrial proceedings (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (Judicial Panel on Multidistrict Litigation)). The lawsuits focus on the claim, supported by at least two research studies, that there is a link between the use of the drug and a type 2 diabetes risk. A 2011 American College of Cardiology study established a connection between the statin and the diabetes risk, and a January 2012 JAMA: Internal Medicine study highlighted the risk in women.**

The Rottenstein Law Group LLP encourages those who have taken Lipitor to download a free informational brochure that discusses potential Lipitor side effects and how to file a Lipitor lawsuit.

*blogs.marketwatch.com/encore/2013/06/19/boomer-drug-of-choice-it-might-be-lipitor/

**archinte.jamanetwork.com/article.aspx?articleid=1108676

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and drugs. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
                            ###

Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/diabetes/prweb10854763.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lipitor Lawsuit News: Rottenstein Law Group LLP Responds to Reports of Lipitor Giveaway
2. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
3. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
4. Lipitor Diabetes Lawsuit Filed by South Carolina Woman Who Developed Type 2 Diabetes Allegedly Due to Lipitor Use, Alonso Krangle Investigating
5. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
6. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
7. Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports
8. Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation
9. Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations
10. NuvaRing Lawsuit News: First New Jersey NuvaRing Trial Scheduled to Start This Week, Rottenstein Law Group LLP Reports
11. C8 Lawsuit News: Wright & Schulte LLC Launches C8 Facebook Page to Provide Up-to-Date Information On C8 Exposure and C8 Lawsuits in Ohio and West Virginia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a ... solutions, today announced that Kyle Allain has joined the company as Vice President ... and operations, including provider, payor and managed care solutions. , A seasoned ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, ... diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into precision ... type of healthcare model in the diagnosis and treatment of brain tumors. Healthcare ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management ... , Rod has been at the forefront of Gardant since it was founded in ... has overseen the opening of more than 40 new senior living communities. With his ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her timeless ... news for single women is that she put all the words in her new ... Joan's insight, personal experiences and sparkling sense of humor have inspired her to write ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs ... makes it difficult for lab operators and management to assess these processes with ... identify wasteful or unnecessary actions. , Created with the help of both ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
Breaking Medicine Technology: